Channel Therapeutics Corporation (CHRO)
Automate Your Wheel Strategy on CHRO
With Tiblio's Option Bot, you can configure your own wheel strategy including CHRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CHRO
- Rev/Share 0.0
- Book/Share -0.6847
- PB -1.7088
- Debt/Equity 0.0
- CurrentRatio 0.1784
- ROIC 2.2486
- MktCap 7717144.0
- FreeCF/Share -0.7234
- PFCF -1.741
- PE -0.9741
- Debt/Assets 0.0
- DivYield 0
- ROE 3.4557
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the “NYSE American”) in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned …
Read More
About Channel Therapeutics Corporation (CHRO)
- IPO Date 2024-02-16
- Website https://channeltherapeutics.com
- Industry Biotechnology
- CEO Francis Knuettel II,
- Employees 4